USANA Health Sciences (NYSE:USNA) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a strong sell rating in a research report sent to investors on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, USANA Health Sciences presently has a consensus rating of “Sell”.

USANA Health Sciences Trading Up 3.6%

Shares of USNA stock opened at $15.43 on Thursday. USANA Health Sciences has a twelve month low of $14.35 and a twelve month high of $32.32. The stock has a fifty day simple moving average of $20.41 and a two-hundred day simple moving average of $19.66. The stock has a market capitalization of $284.84 million, a price-to-earnings ratio of -12.75, a P/E/G ratio of 1.63 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.50). The firm had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Research analysts predict that USANA Health Sciences will post 0.76 EPS for the current fiscal year.

Insider Activity

In other news, CFO G Doug Iiekking sold 5,360 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the sale, the director owned 4,230 shares of the company’s stock, valued at $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 13,869 shares of company stock worth $261,441. 0.82% of the stock is currently owned by company insiders.

Institutional Trading of USANA Health Sciences

Hedge funds have recently modified their holdings of the company. Versant Capital Management Inc boosted its holdings in shares of USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after buying an additional 1,487 shares in the last quarter. National Bank of Canada FI raised its stake in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after acquiring an additional 1,201 shares in the last quarter. State of Wyoming purchased a new stake in USANA Health Sciences during the first quarter valued at approximately $57,000. Tower Research Capital LLC TRC lifted its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after acquiring an additional 3,589 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

More USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its estimates for Q3 2026 EPS to $0.11 from $0.09, Q1 2027 EPS to $0.34 from $0.31, and Q2 2027 EPS to $0.46 from $0.43. These revisions suggest some improvement in the analyst’s near-term outlook.
• Neutral Sentiment: Wall Street Zen lowered its stock rating on USANA, adding to uncertainty around the company’s outlook. USANA Health Sciences Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Sidoti’s broader revisions were substantially bearish: FY2026 EPS was cut to $0.76 from $2.12, FY2027 EPS to $1.77 from $2.77, and Q3 2026 EPS to $0.11 from $0.43 in the latest updates. The firm also reduced estimates for Q4 2026, Q1 2027, Q2 2027, and Q3 2027, although some of those forecasts were later partially raised.
• Negative Sentiment: The estimate cuts follow USANA’s latest quarterly results, in which the company reported a $0.07 per-share loss and revenue of $223.27 million, missing analyst expectations of $0.43 EPS and $235 million in revenue. The company’s FY2026 guidance remains just $0.76 EPS, reinforcing concerns about weak profitability and slowing business momentum.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.